The recently merged NEOMED-LABS / Pacific Biomarkers (NLPBI) has announced the acquisition of PAIRimmune, a non good laboratory practice (GLP) preclinical immunology service provider based in Laval, Quebec.
With more than 20 years of legacy in assay development, immunogenicity and efficacy predictive in vitro and in vivo models, PAIRimmune’s CEO Danielle Poirier and her team have a solid reputation for outstanding science within the community. Since 2015, they have been a contract research organisation (CRO) partner to small biotech, academic groups and the most prestigious vaccine and large molecule pharma companies.
NLPBI President and chief executive officer Dr Benoit Bouche said: “As a science-driven organisation, nothing makes us happier than seeing talented scientists joining forces with us. This acquisition strengthens our ligand binding and neutralization assays R&D capabilities, and this is a determinant growth engine for each of our biomarkers, bioanalytical and vaccine divisions.
“PAIRimmune also increases our capacity and capabilities in flow cytometry and places us in a situation to answer positively to requests with either an in vivo, ex-vivo or immunohistology component. A perfect match!”
This acquisition reinforces NLPBI’s ability to serve the needs of the health industry from the preclinical stage where it is critical to develop robust data needed to make informed go/no-go decisions.
President of PAIRimmune Danielle Poirier said: “The exponential growth of NLPBI these last years is impressive and proves the need for the emergence of a world-class immunology specialist CRO. We are thrilled to become part of this story. Many of our employees are former GSK colleagues and old friends.
“Working in the same building in Laval gives us the feeling that we are already part of the family. Our clients will get access from day one to state-of-the-art labs and synergistic expertise that will result in an improved quality of service.”
PAIRimmune will pursue its operations under the leadership of director of preclinical services Danielle Poirier and associate director of preclinical services Matthieu Daugan.
PAIRimmune will be rebranded later this year, at the same time as NEOMED-LABS and Pacific Biomarkers, under a new corporate identity that is currently in development.
PAIRimmune is a CRO specialised in immunology evaluation for vaccine and immunotherapy development. The company offers scientific methods combined with biopharma expertise to move forward early biological products.
Based on in vivo and in vitro expertise, PAIRimmune builds an adaptive solution for projects in industry, academic and small biotech firms.
The newly merged NEOMED-LABS / Pacific Biomarkers, an immunology centric service provider specialized in assay...
Ampersand Capital Partners has announced that it has completed an acquisition of Pacific Biomarkers and...